---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-011133"
form_type: "8-K"
ticker: "SFES"
cik: "0000086115"
company_name: "SAFEGUARD SCIENTIFICS INC"
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-26T00:11:19.412499+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Safeguard Scientifics Q1 net loss $6.7M; strategic review with Houlihan Lokey continues

## Summary
- Net loss $6.7M ($0.40 per share) vs net income $17.6M ($0.84 per share) in Q1 2021.
- Repurchased 147,795 shares at avg $5.27 in Q1; additional $0.4M post-quarter at $4.71.
- Funded $2.0M convertible loan to Prognos Health and $1.4M to Clutch Holdings.
- Carrying value of ownership interests $24.1M vs cost $154.4M; Bright Health fair value $2.6M.
- Strategic review with Houlihan Lokey ongoing; update expected by Q3 2022 earnings call.

## SEC filing metadata
- accession: 0001437749-22-011133
- form_type: 8-K
- ticker: SFES
- cik: 0000086115
- company_name: SAFEGUARD SCIENTIFICS INC
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/86115/000143774922011133/0001437749-22-011133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/86115/000143774922011133/sfe20220504_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-011133
- JSON: https://secwatch.observer/filing/0001437749-22-011133.json
- Plain text: https://secwatch.observer/filing/0001437749-22-011133.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.